Actively Recruiting
A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications
Led by Royal Brompton & Harefield NHS Foundation Trust · Updated on 2026-01-12
30
Participants Needed
1
Research Sites
29 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To assess the impact on body mass composition from anti-fibrotic medications used in fibrotic lung disease by using BIA and muscle ultrasound
CONDITIONS
Official Title
A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis
- Starting anti-fibrotic medication (nintedanib or pirfenidone) for the first time
- Age over 18 years
- Able to give informed consent willingly
You will not qualify if you...
- Currently require enteral feeding
- Weight loss greater than 10% in the past 3 to 6 months
- Significant musculoskeletal issues affecting muscle mass
- Receiving end of life care with expected survival less than 6 weeks
- Previous use of anti-fibrotic medication
- Taking more than 10 mg daily of prednisolone
- Have an implantable cardioverter defibrillator or permanent pacemaker
- Have heart failure
- Are pregnant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Royal Brompton Hospital
London, United Kingdom, SW36NP
Actively Recruiting
Research Team
J
Jessica Dr Raja
CONTACT
E
Elisabetta Professor Renzoni
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here